InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IMLFF InMed Pharmaceuticals Inc
PNW Pinnacle West Capital Corp
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp

Health Care : Biotechnology | Small Cap Growth
Based in CanadaCompany profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Closing Price
Day's Change
0.0234 (12.58%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

UPDATE: Here's how U.S. brokerage companies rank by one very important measure

7:56 am ET November 22, 2019 (MarketWatch)

By Philip van Doorn, MarketWatch

Returns on invested capital (ROIC) can help identify effective management

U.S. brokers that rely on the discount-trading business model are in play, following Charles Schwab's recent disruptive move to do away with most commissions for online stock trades.

It might be helpful for investors to see which investment banks and broker-dealers have been the best financial performers in recent years. That information is below, based on a screen of data provided by FactSet.

Big broker news

Shares of TD Ameritrade (AMTD) were up 17% Thursday, after CNBC first reported ( the company was working on a deal to be acquired by Schwab (SCHW). The Financial Times reported ( that Schwab was nearing an agreement to pay $25 billion for TD Ameritrade. Shares of Schwab rose 7%.

MarketWatch's Mark DeCambre shows how the two brokers' businesses match up (

Another smaller online competitor to Schwab that might have been an acquisition target is E-Trade Financial (ETFC), whose stock was down as much as 10% early Thursday.

Read:Two powerful reasons to pass on investing in a combined Charles Schwab-TD Ameritrade (

An industry stock screen

A screen of U.S. companies categorized by FactSet as "Investment Banks/Brokers" yields a list of 44 companies. This excludes a large part of the industry.

Financial conglomerates, such as the four biggest U.S. banks (J.P. Morgan Chase (JPM), Bank of America (BAC), Citigroup (C) and Wells Fargo (WFC)), all of which have investment banking and brokerage operations, are excluded.

Investment-banking giants Goldman Sachs (GS) and Morgan Stanley (MS) are on the list. The list also excludes asset managers and life insurance companies, many of which provide investment management and brokerage services to their customers.

For Schwab, TD Ameritrade and E-Trade, low commissions are nothing new, although Schwab's recent push to eliminate most online commissions has pushed the entire industry in that direction. These three companies have relied heavily on interest income from deposits that their brokerage customers place in their subsidiary banks. A change in Federal Reserve policy leading to three recent cuts in the federal funds rate has put pressure on this profit center.

All that said, the industry is in flux with the interest-rate challenge, much lower commission revenue, the requirement for very expensive investments in technology and M&A activity. So how can we gauge the group's performance?

One way is to look at their returns on invested capital (ROIC) over the past five full years. FactSet defines ROIC as a company's net income divided by total invested capital (total shareholders' equity and long-term debt). The idea of ROIC is to measure how efficiently a company's managers use the money they have raised.

We pared the list of 44 companies to 25 with market capitalizations of at least $500 million and for which five full fiscal years of ROIC data were available.

Here they are, sorted by average ROIC over the past five full fiscal years:

Company Ticker Average ROIC - past five full fiscal years Market capitalization ($ million)

Cboe Global Markets Inc. US:CBOE 48.3% $13,671

MarketAxess Holdings Inc. US:MKTX 28.0% $15,340

Lazard Ltd. Class A US:LAZ 24.5% $3,926

Evercore Inc. Class A US:EVR 19.8% $3,042

Moelis & Co. Class A US:MC 18.4% $1,642

Houlihan Lokey Inc. Class A US:HLI 14.8% $1,992

TD Ameritrade Holding Corp. US:AMTD 14.0% $22,413

Ameriprise Financial Inc. US:AMP 12.1% $20,066

Charles Schwab Corp. US:SCHW 11.2% $57,382

Interactive Brokers Group Inc. Class A US:IBKR 8.6% $3,626

Intercontinental Exchange Inc. US:ICE 8.4% $52,611

CME Group Inc. Class A US:CME 8.3% $74,052

LPL Financial Holdings Inc. US:LPLA 7.9% $7,379

INTL FCStone Inc. US:INTL 6.9% $755

E-TRADE Financial Corp. US:ETFC 6.8% $10,361

Virtu Financial Inc. Class A US:VIRT 6.3% $1,960

Stifel Financial Corp. US:SF 5.0% $4,203

Nasdaq Inc. US:NDAQ 4.9% $17,326

B. Riley Financial Inc. US:RILY 4.2% $770

BGC Partners Inc. Class A US:BGCP 3.4% $1,708

Morgan Stanley US:MS 2.7% $79,473

Goldman Sachs Group Inc. US:GS 2.6% $77,159

Ladenburg Thalmann Financial Services Inc. US:LTS 2.2% $518

Piper Jaffray Cos. US:PJC 1.8% $1,137

Jefferies Financial Group Inc. US:JEF 1.0% $6,090

Source: FactSet

You can click on the tickers for more about each company, including business profiles, which vary widely.

Leaving the list in the same order, here's a summary of sell-side analysts' opinions of the stocks. Price targets and closing prices are as of Nov. 20, which means they are outdated for Schwab and TD Ameritrade, at least.

Company Ticker Share 'buy' ratings Share neutral ratings Share 'sell' ratings Closing price - Nov. 20 Consensus price target Implied 12-month upside potential

Cboe Global Markets Inc. US:CBOE 40% 53% 7% $123.32 $121.00 -2%

MarketAxess Holdings Inc. US:MKTX 0% 82% 18% $404.49 $325.00 -20%

Lazard Ltd. Class A US:LAZ 33% 45% 22% $37.38 $39.50 6%

Evercore Inc. Class A US:EVR 67% 33% 0% $77.84 $91.38 17%

Moelis & Co. Class A US:MC 62% 38% 0% $33.27 $39.75 19%

Houlihan Lokey Inc. Class A US:HLI 62% 38% 0% $47.70 $52.71 11%

TD Ameritrade Holding Corp. US:AMTD 37% 42% 21% $41.38 $39.43 -5%

Ameriprise Financial Inc. US:AMP 69% 31% 0% $158.38 $171.20 8%

Charles Schwab Corp. US:SCHW 42% 47% 11% $44.75 $43.20 -3%

Interactive Brokers Group Inc. Class A US:IBKR 50% 33% 17% $47.24 $51.40 9%

Intercontinental Exchange Inc. US:ICE 78% 17% 6% $94.48 $102.82 9%

CME Group Inc. Class A US:CME 33% 50% 17% $206.64 $216.06 5%

LPL Financial Holdings Inc. US:LPLA 42% 58% 0% $91.29 $94.11 3%

(MORE TO FOLLOW) Dow Jones Newswires

November 22, 2019 07:56 ET (12:56 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.